Clinical trial NCT00665925 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: fostamatinib disodium (r935788), fostamatinib disodium (r935788), placebo
SMILES: COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC, COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must give written informed consent by signing an IRB/EC-approved Informed
             Consent Form (ICF) prior to admission to this study.

          -  Males and females, 18 years of age or older, with active RA for at least 6 months
             prior to Day 1 dosing.

          -  Patients must have been receiving weekly methotrexate doses (7.5-25 mg/week) for a
             minimum of 3 months prior to Day 1 dosing and must be receiving a stable MTX dose,
             with no change in route, for the previous 6 weeks prior to Day 1 dosing.

        'Patients must be receiving a folic or folinic acid supplementation at a stable dose for at
        least 6 weeks prior to Day 1 dosing.

          -  Females of childbearing potential must be fully informed of the potential for R788 to
             adversely affect the fetus and, if sexually active, must agree to use a well
             established method of birth control during the study (oral contraceptive, mechanical
             barrier, long acting hormonal agent). These patients must not be lactating and must
             have a negative urine pregnancy test at the time of randomization and at each
             laboratory determination.

          -  The patient must otherwise be in good health as determined by the Investigator on the
             basis of medical history, physical examination, and laboratory screening tests during
             the screening period. See exclusion criteria for specific exclusions.

          -  In the Investigator's opinion, the patient has the ability to understand the nature of
             the study and any hazards of participation, and to communicate satisfactorily with the
             Investigator and to participate in, and to comply with, the requirements of the entire
             protocol.

        Exclusion Criteria:

          -  The patient has a history of, or a concurrent, clinically significant illness, medical
             condition (other than arthritis) or laboratory abnormality that, in the Investigator's
             opinion, could affect the conduct of the study. Specifically, excluded are patients
             with the following:

               1. uncontrolled or poorly controlled hypertension;

               2. other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder)
                  or arthritis syndromes (gout, Lyme disease, Reiter's syndrome);

               3. recent (within past 2 months prior to Day 1 dosing) serious surgery or infectious
                  disease;

               4. recent history (past 5 years prior to Day 1 dosing) of, or treatment for, a
                  malignancy other than nonmelanomatous skin cancer, or any history of lymphoma;

               5. Hepatitis B ;

               6. Hepatitis C ;

               7. interstitial pneumonitis or active pulmonary infection on chest x-ray;

               8. Tuberculosis (TB): the TB skin test should be negative.

               9. known laboratory abnormalities.

          -  The patient has a history of substance abuse, drug addiction or alcoholism. Patients
             may consume up to 4 units of alcohol per week; however, alcohol should be avoided in
             the 72 hours prior to lab assessments. Patients who cannot reliably comply with this
             should be excluded. A unit of alcohol is defined as the following: Beer=12 oz or 355
             mL; wine = 5 oz or 148 mL; sweet dessert wine=3 oz or 89 mL; 80 proof distilled
             spirits= 1.5 oz or 44 mL.

          -  The patient has been treated previously treated with R788 under a different protocol.